Advertisement
Screener

GALECTIN THERAPEUTICS INC. (GALT) Graph

GALT Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $2.13M; Operating expenses $3.98M; Net income -$9.11M.
  • 2026-03-31: Research and development $2.23M; Operating expenses $4.08M; Net income -$5.05M.
  • 2025-12-31: Research and development $1.93M*; Operating expenses $3.37M*; Net income -$5.50M*.
  • 2025-09-30: Research and development $2.61M; Operating expenses $4.20M; Net income -$8.18M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$2.13M$3.98M-$9.11M
2026-03-31$2.23M$4.08M-$5.05M
2025-12-31$1.93M*$3.37M*-$5.50M*
2025-09-30$2.61M$4.20M-$8.18M
2025-06-30$3.26M$4.63M-$7.52M
2025-03-31$6.49M$7.90M-$9.63M
2024-09-30$7.59M$9.07M-$11.22M
2024-06-30$9.81M$11.29M-$12.37M
2024-03-31$8.05M$9.65M-$11.49M
2023-09-30$7.73M$9.17M-$10.43M
2023-06-30$7.37M$9.00M-$9.11M
2023-03-31$8.80M$10.34M-$11.53M
2022-09-30$6.60M$8.12M-$8.60M
2022-06-30$8.07M$9.66M-$9.61M
2022-03-31$8.06M$9.94M-$9.93M
2021-09-30$6.61M$8.24M-$8.52M
2021-06-30$6.45M$8.19M-$8.45M
2021-03-31$4.90M$6.32M-$6.34M
2020-09-30$4.78M$5.93M-$5.94M
2020-06-30$4.68M$6.10M-$6.11M
2020-03-31$2.14M$3.58M-$3.56M
2019-09-30$1.50M$2.86M-$2.78M
2019-06-30$1.52M$3.02M-$3.00M
2019-03-31$646.00K$2.37M-$2.38M
2018-09-30$1.50M$2.68M-$2.75M
2018-06-30$1.48M$3.76M-$3.84M
2018-03-31$2.30M$4.18M-$4.26M
2017-09-30$3.50M$4.41M-$4.41M
2017-06-30$3.44M$4.51M-$4.51M
2017-03-31$3.77M$4.95M-$4.94M
2016-09-30$3.29M$4.54M-$4.53M
2016-06-30$4.23M$5.53M-$5.52M
2016-03-31$4.38M$6.81M-$6.80M
2015-12-31(m)(m)-$4.67M
2015-09-30$4.46M$5.90M-$5.89M
2015-06-30$2.60M$4.66M-$4.64M
2015-03-31$3.14M$4.84M-$4.83M
2014-12-31(m)(m)-$3.73M
2014-09-30$1.98M$3.48M-$3.52M
2014-06-30$1.59M$3.38M-$3.43M
2014-03-31$2.77M$4.84M-$5.11M
2013-12-31(m)(m)-$2.80M
2013-09-30$1.19M$3.54M-$3.54M
2013-06-30$1.35M$2.55M-$2.54M
2013-03-31$1.75M$3.21M-$3.20M
2012-09-30$1.41M$2.90M-$2.69M
2012-06-30$1.22M$2.67M-$2.66M
2012-03-31$901.00K$1.95M-$1.95M
2011-09-30$655.00K$2.03M-$2.03M
2011-06-30$1.29M$2.99M-$3.13M
2011-03-31$744.00K$2.01M-$2.39M
2010-09-30$313.00K$1.21M-$1.11M
2010-06-30$234.00K$1.35M-$1.65M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$4.37M$8.06M-$14.16M
2025-06-30$9.75M$12.52M-$17.15M
2024-06-30$17.87M$20.94M-$23.86M
2023-06-30$16.17M$19.34M-$20.64M
2022-06-30$16.13M$19.60M-$19.55M
2021-06-30$11.35M$14.51M-$14.79M
2020-06-30$6.83M$9.69M-$9.67M
2019-06-30$2.17M$5.39M-$5.37M
2018-06-30$3.77M$7.94M-$8.10M
2017-06-30$7.22M$9.46M-$9.45M
2016-06-30$8.60M$12.35M-$12.32M
2015-06-30$5.74M$9.50M-$9.47M
2014-06-30$4.37M$8.22M-$8.54M
2013-06-30$3.10M$5.75M-$5.75M
2012-06-30$2.12M$4.62M-$4.61M
2011-06-30$2.04M$5.00M-$5.52M
2010-06-30$363.00K$2.38M-$3.79M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesNet income
2025-09-30$12.36M$16.72M-$25.34M
2024-09-30$25.46M$30.00M-$35.08M
2023-09-30$23.90M$28.51M-$31.07M
2022-09-30$22.73M$27.72M-$28.14M
2021-09-30$17.96M$22.75M-$23.31M
2020-09-30$11.61M$15.61M-$15.61M
2019-09-30$3.67M$8.25M-$8.16M
2018-09-30$5.28M$10.62M-$10.85M
2017-09-30$10.72M$13.87M-$13.85M
2016-09-30$11.89M$16.88M-$16.84M
2015-09-30$10.20M$15.40M-$15.36M
2014-09-30$6.34M$11.70M-$12.06M
2013-09-30$4.29M$9.30M-$9.29M
2012-09-30$3.52M$7.52M-$7.30M
2011-09-30$2.69M$7.04M-$7.55M
2010-09-30$676.00K$3.59M-$4.90M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$14.29M$20.09M$0.00-$30.84M
2024-12-31$36.57M$42.43M$0.00-$47.05M
2023-12-31$32.13M$38.07M(m)-$41.07M
2022-12-31$31.74M$38.35M(m)-$38.78M
2021-12-31$23.82M$30.18M(m)-$30.53M
2020-12-31$17.98M$23.44M(m)-$23.46M
2019-12-31$7.47M$13.44M(m)-$13.29M
2018-12-31$6.47M$13.60M(m)-$13.90M
2017-12-31$11.72M$16.25M(m)-$16.23M
2016-12-31$15.32M$21.48M(m)-$21.44M
2015-12-31$13.11M$20.08M(m)-$20.03M
2014-12-31$8.43M$15.43M(m)-$15.79M
2013-12-31$5.69M$12.10M(m)-$12.09M
2012-12-31$4.53M$9.90M(m)-$9.68M
2011-12-31$3.55M$10.41M(m)-$10.91M
2010-12-31$1.07M$4.88M(m)-$5.63M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Rezolute, Inc. (RZLT)United States$0.382B-6.45
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63